MyBiotics innovative technologies; MyCrobeTM and SuperDonorTM allow us to be in the front of the microbiome field. Both technologies resolve the three critical factors in the probiotic development market. Delivery, Targeting and Colonization. MyCrobeTM and SuperDonorTM provide single or multi-bacterial combinations for targeted treatment, wholemicrobiome restoration and the first actual screening method to replace FMT microbiome transplantations. MyBiotics focus is to return the bacterial population to its healthy and balanced state by using live bacteria that will colonize and compete with the existent disease-promoting population.

Health & Wellness

Pharmaceutical

Health Care

Biotechnology

Mybiotics Pharma LTD

Didi Daboush

Motty Hershkowitz

Lior Weissman

Eran Kosover

Dorit Rozner, Ph.D

Mybiotics Pharma LTD

Org chart

Similar companies